Axovant Sciences Ltd. (AXON) Reaches $2.09 After 6.00% Down Move; Shorts at Cpfl Energia SA (CPL) Raised By 84.26%

January 14, 2018 - By Nellie Frank

The stock of Axovant Sciences Ltd. (NASDAQ:AXON) is a huge mover today! The stock decreased 7.93% or $0.18 during the last trading session, reaching $2.09. About 4.64 million shares traded or 196.02% up from the average. Axovant Sciences Ltd. (NASDAQ:AXON) has risen 97.46% since January 14, 2017 and is uptrending. It has outperformed by 80.76% the S&P500.The move comes after 9 months negative chart setup for the $225.11 million company. It was reported on Jan, 14 by Barchart.com. We have $1.96 PT which if reached, will make NASDAQ:AXON worth $13.51M less.

Cpfl Energia SA (NYSE:CPL) had an increase of 84.26% in short interest. CPL’s SI was 525,700 shares in January as released by FINRA. Its up 84.26% from 285,300 shares previously. With 887,600 avg volume, 1 days are for Cpfl Energia SA (NYSE:CPL)’s short sellers to cover CPL’s short positions. The stock decreased 2.74% or $0.35 during the last trading session, reaching $12.43. About 140,629 shares traded. CPFL Energia S.A. (NYSE:CPL) has risen 54.85% since January 14, 2017 and is uptrending. It has outperformed by 38.15% the S&P500.

CPFL Energia S.A., together with its subsidiaries, generates, transmits, distributes, and commercializes electricity to residential, industrial, and commercial clients in Brazil. The company has market cap of $6.60 billion. The firm generates electricity through wind, biomass-powered thermal, solar, and hydroelectric power plants. It has a 24.09 P/E ratio. It also makes, commercializes, rents, and maintains electro-mechanical equipment; and offers administrative, call center, collection, IT, telecommunication, energy transmission, and energy efficiency management services, as well as maintenance services for energy generation companies.

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. The company has market cap of $225.11 million. The Company’s lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of AlzheimerÂ’s disease; in Phase IIb clinical trial for treating dementia with Lewy bodies ; and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. It currently has negative earnings. The firm is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD.

Analysts await Axovant Sciences Ltd. (NASDAQ:AXON) to report earnings on February, 13. They expect $-0.49 earnings per share, down 2.08% or $0.01 from last year’s $-0.48 per share. After $-0.64 actual earnings per share reported by Axovant Sciences Ltd. for the previous quarter, Wall Street now forecasts -23.44% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>